9.00 – 9.30 a.m.
9.30 – 10.00 a.m.
10.00 – 10.30 a.m.
10.30 – 10.40 a.m. |
Chemotherapy-induced surge in endothelial precursor cells:
Implications for antiangiogenic drugs as chemosensitizing
agents
Y. Shaked, Canada
Evaluation of biomarkers during clinical development of
anti-angiogenic agents
S. Scherer, Basel
Anti-intergrin antibodies - status of clinical development
Z. Lang, Centocor, USA
Free communication
avß3 integrin expression in gliomas correlates with tumor
grade and is not restricted to tumor vasculature
O. Schnell, Munich
|
11.10 – 12.40 a.m.
11.10 – 11.40 a.m.
11.40 – 12.10 a.m.
12.10 – 12.40 a.m.
12.40 – 12.50 a.m.
1.00 p.m.
|
Angiogenesis
Chair: W. Berdel, V. Nuessler
Clinical development of bevacizumab
G. Massimini, Basel
Experimental results with targeted constructs of
truncated tissue factor for tumor vessel occlusion
W.E. Berdel, Muenster
Metastatic activity and therapy resistance in human
pancreatic cancer – infl uence of cancer stem cells
Christiane Bruns, Munich
Closing remarks by Heinz Zwierzina
End of meeting |